UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (37619) 37619
Newsletter (13) 13
Magazine Article (12) 12
Book / eBook (10) 10
Publication (10) 10
Book Chapter (6) 6
Newspaper Article (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34992) 34992
science & technology (31068) 31068
life sciences & biomedicine (29609) 29609
oncology (21236) 21236
female (19861) 19861
antineoplastic combined chemotherapy protocols - therapeutic use (17854) 17854
male (14736) 14736
middle aged (12428) 12428
adult (10502) 10502
aged (10362) 10362
animals (10098) 10098
pharmacology & pharmacy (9053) 9053
cancer (8593) 8593
cell line, tumor (8071) 8071
chemotherapy (7845) 7845
antineoplastic combined chemotherapy protocols - pharmacology (7593) 7593
antineoplastic agents - pharmacology (6970) 6970
antineoplastic combined chemotherapy protocols - adverse effects (6838) 6838
treatment outcome (6779) 6779
mice (6376) 6376
apoptosis - drug effects (5030) 5030
antineoplastic combined chemotherapy protocols - administration & dosage (4565) 4565
apoptosis (4564) 4564
antineoplastic agents - therapeutic use (4543) 4543
drug synergism (4403) 4403
care and treatment (4002) 4002
breast neoplasms - drug therapy (3943) 3943
dose-response relationship, drug (3912) 3912
research (3842) 3842
medicine & public health (3752) 3752
cell proliferation - drug effects (3619) 3619
cisplatin - administration & dosage (3443) 3443
tumors (3415) 3415
xenograft model antitumor assays (3266) 3266
lung neoplasms - drug therapy (3250) 3250
combined modality therapy (3162) 3162
analysis (3135) 3135
neoplasms - drug therapy (3076) 3076
pharmacology/toxicology (3068) 3068
aged, 80 and over (3024) 3024
prognosis (3014) 3014
disease-free survival (3010) 3010
cancer therapies (2990) 2990
drug administration schedule (2968) 2968
fluorouracil - administration & dosage (2957) 2957
breast cancer (2943) 2943
antineoplastic agents (2822) 2822
drug therapy (2720) 2720
mice, nude (2710) 2710
health aspects (2692) 2692
survival analysis (2649) 2649
antineoplastic agents - administration & dosage (2612) 2612
doxorubicin - administration & dosage (2611) 2611
antimitotic agents (2575) 2575
cancer research (2555) 2555
drug resistance, neoplasm (2555) 2555
adolescent (2552) 2552
neoplasm staging (2448) 2448
hematology (2431) 2431
cell survival - drug effects (2391) 2391
deoxycytidine - analogs & derivatives (2385) 2385
survival rate (2315) 2315
breast neoplasms - pathology (2266) 2266
metastasis (2264) 2264
cyclophosphamide - administration & dosage (2236) 2236
time factors (2150) 2150
cell biology (2036) 2036
carcinoma, non-small-cell lung - drug therapy (2013) 2013
signal transduction - drug effects (2010) 2010
tumor cells, cultured (1988) 1988
clinical trials (1983) 1983
proteins (1940) 1940
cisplatin (1893) 1893
paclitaxel - administration & dosage (1865) 1865
pharmacology (1796) 1796
neoplasm metastasis (1779) 1779
clinical trials as topic (1776) 1776
research article (1757) 1757
deoxycytidine - administration & dosage (1752) 1752
child (1748) 1748
medicine (1738) 1738
gene expression (1713) 1713
antineoplastic agents - adverse effects (1705) 1705
colorectal neoplasms - drug therapy (1704) 1704
kinases (1685) 1685
drug resistance (1669) 1669
mice, inbred balb c (1665) 1665
retrospective studies (1639) 1639
lung neoplasms - pathology (1636) 1636
science & technology - other topics (1577) 1577
medicine, research & experimental (1550) 1550
research & experimental medicine (1550) 1550
cisplatin - pharmacology (1549) 1549
biochemistry & molecular biology (1539) 1539
studies (1538) 1538
colorectal cancer (1533) 1533
patients (1492) 1492
ovarian neoplasms - drug therapy (1488) 1488
follow-up studies (1486) 1486
cytotoxicity (1479) 1479
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (37255) 37255
Japanese (325) 325
Chinese (109) 109
German (73) 73
French (72) 72
Russian (69) 69
Spanish (42) 42
Italian (22) 22
Portuguese (17) 17
Polish (15) 15
Hungarian (12) 12
Norwegian (9) 9
Dutch (7) 7
Croatian (6) 6
Hebrew (3) 3
Swedish (3) 3
Czech (1) 1
Finnish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Investigational new drugs, ISSN 1573-0646, 01/2010, Volume 29, Issue 3, pp. 489 - 498
Journal Article
Journal Article
Cancer biology & therapy, ISSN 1538-4047, 10/2014, Volume 13, Issue 11, pp. 1072 - 1081
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 03/2010, Volume 28, Issue 8, pp. 1387 - 1394
Purpose Src family kinase (SFK) proteins are frequently activated in cancer and can coordinate tumor cell growth, survival, invasion, and angiogenesis. Given... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Male | Thiazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug-Related Side Effects and Adverse Reactions | Adult | Female | Quinazolines - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Drug Administration Schedule | Pyrimidines - administration & dosage | Vascular Endothelial Growth Factor A - blood | Pyrimidines - pharmacology | Fibroblast Growth Factor 2 - blood | Biomarkers, Pharmacological - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Quinazolines - adverse effects | Pyrimidines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Index Medicus | Original Reports | Thor11 | Thor2
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 12/2012, Volume 71, Issue 2, pp. 523 - 530
Journal Article
Investigational new drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 159 - 168
...), and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients with advanced solid tumors... 
Medicine & Public Health | Sorafenib | VEGF inhibition | Phase I trial | Oncology | Advanced tumors | MET RTK inhibition | Pharmacology/Toxicology | Tivantinib | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-met - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Pyrrolidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Quinolines - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyrrolidinones - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Neoplasms - genetics | Phenylurea Compounds - adverse effects | Pyrrolidinones - pharmacology | Aged, 80 and over | Niacinamide - pharmacokinetics | Adult | Female | Phenylurea Compounds - pharmacokinetics | Pyrrolidinones - adverse effects | Niacinamide - adverse effects | Cytochrome P-450 CYP2C19 - genetics | Treatment Outcome | Neoplasms - drug therapy | Niacinamide - administration & dosage | Polymorphism, Genetic | Maximum Tolerated Dose | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Quinolines - adverse effects | Chemotherapy, Combination | Usage | Research | Drug therapy | Tumors | Studies | Clinical trials | Inhibitor drugs | Pharmaceutical sciences | Index Medicus | Phase I Studies
Journal Article
Journal Article